Drug class
S-enantiomer of ketamine; non-selective, non-competitive NMDA receptor antagonist
Mechanism of action
Non-competitively antagonises NMDA glutamate receptors. Its antidepressant effects may involve downstream changes in synaptic plasticity and glutamatergic signalling; the precise mechanism underlying clinical response is not fully established.
General use cases
- Treatment-resistant depression in adults, in conjunction with an oral antidepressant under the US product indication
- Depressive symptoms in adults with major depressive disorder and acute suicidal ideation or behaviour, in conjunction with standard care; the label does not establish prevention of suicide or reduction of suicidal behaviour
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
